ScienceDaily (Oct. 29, 2012) An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found.
The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.
“Oral mucositis or mouth sores is a painful and debilitating side effect of radiation therapy,” states principal investigator Robert Miller, M.D., a radiation oncologist at Mayo Clinic. “Our findings represent a new standard of care for treating this condition.”
Doxepin rinse does not cause the side effects associated with narcotic pain medicines, Dr. Miller says.
The Phase III study assessed the effectiveness of doxepin oral rinse versus placebo in 155 patients receiving radiation therapy for head and neck cancer. Patients received a single blinded dose of doxepin on day one and crossed over to the opposite study arm on a subsequent day. Patients reported pain associated with oral mucositis on a pain questionnaire with a scale of 0 to 10 administered at baseline and then at five, 15, 30, 60, 120 and 240 minutes after rinsing with doxepin. Patients could continue doxepin after the study, and 64 percent did so. Doxepin was well tolerated, though stinging, burning, unpleasant taste and drowsiness were reported as side effects.
Mayo Clinic researchers involved in the study also included Rui Qin, Ph.D., James Martenson, M.D., Robert Foote, M.D. and Charles Loprinzi, M.D.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
The above story is reprinted from materials provided by Mayo Clinic.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
- Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia
- Impact of Medicaid expansion would vary by state, according to study
- Fish, But Not Fish Oil Supplements, May Shield Against Stroke
- Study: More Birth Defects with In Vitro
- Antidepressants and Stroke
- Vaccine Safety
- Children and CT Concerns
- Study: Hint of Benefit for Alzheimer’s Drug
- Study provides direct evidence for persistent activity in medial entorhinal cortex layer neurons
- Moderate Alcohol Consumption May Increase Risk of Atrial Fibrillation
Submited at Monday, October 29th, 2012 at 4:15 pm on Uncategorized by jessica
Comment RSS 2.0 - leave a comment - trackback